Currently, there are no clinical trials on DcR3 however, there are several ongoing in breast cancer for blockading CTLA4, TGF-β, PD-1/PD-L1, CLTA4 and PD-1, and chimeric antigen receptor T-cell therapy (CAR-T). Here, CD274 is linked to breast carcinoma.